Press Releases

PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes INCLINE VILLAGE, Nev., Sept. 7, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced adjustments to the conversion rates for: The 2.875% Convertible Senior Notes due February 15, 2015

PDL BioPharma Announces Second Quarter 2011 Financial Results INCLINE VILLAGE, Nev., July 27, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2011 . Total revenues for the second quarter of 2011 were

PDL BioPharma Announces Second Quarter 2011 Financial Results on July 27, 2011 INCLINE VILLAGE, Nev., July 20, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30,

INCLINE VILLAGE, Nev., July 11, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced a favorable ruling today, specifically, that on July 7, 2011 , the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F.

PDL BioPharma Announces Retirement of $133.5 Million of 2.00% Convertible Senior Notes Due February 2012 INCLINE VILLAGE, Nev., July 5, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has completed the retirement of the remaining $133.5 million in

PDL BioPharma Completes Regular Quarterly Dividend Payment INCLINE VILLAGE, Nev., June 16, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 15, 2011 , regular quarterly dividend payment of $0.15 per share to all stockholders owning

PDL BioPharma Revises Second Quarter 2011 Revenue Guidance to $122 Million INCLINE VILLAGE, Nev., June 9, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today revised its guidance for the second quarter ending June 30, 2011 , to approximately $122 million , as compared

PDL BioPharma Announces Conversion Rate Adjustments for its Convertible Notes INCLINE VILLAGE, Nev., June 6, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced an adjustment to the conversion rate for: The 2.00% Convertible Senior Notes due February 15, 2012

PDL BioPharma Provides Second Quarter 2011 Revenue Guidance of $128 Million INCLINE VILLAGE, Nev., June 1, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2011 , of approximately $128 million , as

PDL BioPharma Issues Redemption Notice for Its 2.00% Convertible Senior Notes Due February 15, 2012 INCLINE VILLAGE, Nev., May 24, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that on June 30, 2011 , it will redeem all of the Company's outstanding 2.00%

PDL BioPharma, Inc. Completes Issuance of $155.25 Million of Convertible Senior Notes Due May 2015 INCLINE VILLAGE, Nev., May 16, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced it has completed the issuance of $155.25 million in aggregate

PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015 INCLINE VILLAGE, Nev., May 10, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced it has agreed to sell $135.0 million aggregate principal amount of its

PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 INCLINE VILLAGE, Nev., May 9, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced that it intends to offer, subject to market and other

PDL BioPharma to Present at Upcoming Conferences INCLINE VILLAGE, Nev., May 3, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the following upcoming

Conference Call Today at 4:30 p.m. Eastern Time -